Last reviewed · How we verify

Chronic Iron Overload — Treatment Landscape & Competitive Intelligence

Chronic Iron Overload (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Iron Overload, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Exjade DEFERASIROX Novartis Iron Chelator [EPC] Flavin reductase (NADPH) 2005-01-01
Desferal DEFEROXAMINE Mitem Pharma Iron Chelator Deoxyhypusine hydroxylase 1968-01-01
Exjade Exjade DisperSol Technologies, LLC Flavin reductase (NADPH), Lysine-specific demethylase 5A
desferrioxamine desferrioxamine Brigham and Women's Hospital Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Brigham and Women's Hospital · 1 drug in Chronic Iron Overload
  2. DisperSol Technologies, LLC · 1 drug in Chronic Iron Overload
  3. Mitem Pharma · 1 drug in Chronic Iron Overload
  4. Novartis · 1 drug in Chronic Iron Overload

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Iron Overload:

Cite this brief

Drug Landscape (2026). Chronic Iron Overload — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-iron-overload. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing